Marla Mills-Wilson

Marla Mills-Wilson is a 24+ year clinical research veteran who brings to Galectin Therapeutics a deep experience in not only program management but also project management, study operations, site management, and progression across Phase I to IV in a variety of therapeutic indications, including liver-related diseases, oncology, ophthalmology, and vaccines. Prior to joining Galectin Therapeutics, she spent the previous four years working in the rare liver disease space. She partnered and consulted with CymaBay Therapeutics to lead its global phase III Primary Biliary Cirrhosis program. Preceding CymaBay, Marla collaborated with Intercept Pharmaceuticals, where she was responsible for leading its global phase III fibrosis due to the NASH study. Prior positions include serving as Director at INNO Clinical Outcomes, clinical operations management and oversight at Novella, Jubilant Clinsys, Inspire Pharmaceuticals, Glaxo Wellcome, and Parexel – working cross-functionally in an assortment of roles.

Marla is named a contributor to multiple ophthalmology manuscripts and posters. She also is a tremendous advocate of process improvement and is lean Six Sigma certified. She holds a B.S. from the University of Tennessee at Chattanooga and continues to be a member of several professional clinical research organizations.